Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL712435

CC(C)Oc1ccc(OCc2ccccc2F)cc1-c1nc2cccnc2[nH]1.O=C(O)C(F)(F)F

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMO Q99835 1/20 0.40
PTPN1 P18031 5/20 0.40
GCK P35557 1/20 0.40
PARP15 Q460N3 1/20 0.38
PARP10 Q53GL7 1/20 0.38
PTPN2 P17706 3/20 0.37
CDC25B P30305 3/20 0.37
SCN9A Q15858 1/20 0.37
PPARG P37231 1/20 0.37
LRRK2 Q5S007 1/20 0.37
CYP1A1 P04798 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP1B1 Q16678 1/20 0.36
MAOB P27338 2/20 0.36
CSNK2A2 P19784 1/20 0.36
CSNK2A1 P68400 1/20 0.36
SGMS2 Q8NHU3 1/20 0.36
MAPT P10636 2/20 0.36
MAPK1 P28482 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL709562 0.94 SMO (0.40) SMOPTPN1GCKPARP15PARP10
SCHEMBL10206657 0.93 SMO (0.40) SMOPTPN1GCKPARP15PARP10
Trifluoroacetic Acid SCHEMBL711385 0.90 CYP3A4 (0.39) LRRK2CYP1A2MAOBKDM4E
Trifluoroacetic Acid SCHEMBL709855 0.89 SMO (0.41) SMOPTPN1PARP15PARP10PTPN2
Trifluoroacetic Acid SCHEMBL708957 0.87 MAOB (0.36) PPARGLRRK2MAOB
Trifluoroacetic Acid SCHEMBL711107 0.86 GPR132 (0.43) PPARG
SCHEMBL10206665 0.85 SMO (0.40) SMOGCKPARP15PARP10SCN9A
Trifluoroacetic Acid SCHEMBL709930 0.85 GCK (0.48) SMOPTPN1GCKPTPN2CDC25B
Trifluoroacetic Acid SCHEMBL711226 0.84 SMO (0.41) SMOPTPN1PARP15PARP10PTPN2
Trifluoroacetic Acid SCHEMBL710214 0.83 PDE4A (0.40) GCKPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1940837-B1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2012-11-07 EP disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US disclosed
EP-1940837-A2 IMIDAZOPYRIDINE COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2008-07-09 EP disclosed
WO-2007028135-A2 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS GCK, GCKR, KHK SMO 4431/4885PTPN1 3316/4885GCK 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.